Intellikine has initiated a multicentre Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.
INK1117 is a selective, orally available, small molecule inhibitor of the PI3Kalpha isoform.
The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetic profile of the PI3Kalpha selective inhibitor.
In PI3Kalpha mutant-specific preclinical tumour models, INK1117 has demonstrated good efficacy results.
Vall d’Hebron University Hospital, Barcelona, Medical Oncology Department head Josep Tabernero said they will explore INK1117 in cancer patients, particularly those whose tumours have a mutation of the PIK3CA gene.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData